Medicare Providers

Medical Clinical Policy Updates

April 25, 2022 

The following Medicare Clinical Policies contain changes to their previous versions, have been approved for use by Medicare QIC and will be effective
May 25, 2022:

• Clinical Practice and Preventive Health Guidelines
• CP.MP.31 Cosmetic and Reconstructive Procedures
• CP.MP.50 Drugs of Abuse Definitive Testing
• CP.MP.53 Ferriscan R2-MRI
• CP.MP.54 Hospice
• CP.MP.55 Assisted Reproductive Technology
• CP.MP.70 Proton and Neutron Beam Therapies
• CP.MP.84 Cell-free Fetal DNA Testing
• CP.MP.89 Genetic and Pharmacogenetic Testing
• CP.MP.91 Obstetrical Home Care Programs
• CP.MP.95 Gender Affirming Procedures
• CP.MP.101 Donor Lyphocyte Infusion
• CP.MP.107 DME and Orthotics and Prosthetics Guidelines
• CP.MP.108 AHCT for Sickle Cell Anemia
• CP.MP.113 Holter Monitors
• CP.MP.127 Total Artificial Heart
• CP.MP.138 Pediatric Heart Transplant
• CP.MP.142 Urinary Incontinence Devices and Treatments
• CP.MP.144 Mechanical Stretch Devices
• CP.MP.145 Electric Tumor Treating Fields
• CP.MP.151 Transcatheter Closure of Patent Foraen Ovale
• CP.MP.152 Measurement of Serum 1,25- Vit D
• CP.MP.170 Nerve Blocks and Neurolysis for Pain Management
• CP.MP.180 Implantable Hypoglossal Nerve Stim
• CP.MP.182 Short Inpatient Hospital Stay
• CP.MP.186 Burn Surgery
• CP.MP.190 Oxygen Use and Concentrators
• CP.MP.203 Diaphragmatic Phrenic Nerve Stimulation
• CP.MP.209 GI Pathogen Nucleic Acid Detection Panel Testing